Supernus Pharmaceuticals SUPN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $207.71M+38.6% | $211.57M+21.5% | $192.1M+9.3% | $165.45M-1.7% | $149.82M+4.3% | ||
| $23.39M+48.4% | $23.01M-11.8% | $18.97M+7.9% | $16.83M-6.1% | $15.76M-3.3% | ||
| $184.31M+37.5% | $188.57M+27.4% | $173.14M+9.5% | $148.63M-1.2% | $134.06M+5.3% | ||
| 88.7%-0.7pp | 89.1%+4.1pp | 90.1%+0.1pp | 89.8%+0.5pp | 89.5%+0.8pp | ||
| $39.44M+46.5% | $27.83M-2.9% | $29.37M+1.1% | $22.12M-15.5% | $26.93M+8.0% | ||
| $125.17M+39.2% | $122.39M+54.1% | $179.68M+158% | $93.55M+8.9% | $89.94M+4.0% | ||
| $8.48M+5.1% | —— | —— | —— | $8.07M— | ||
| $27.4M+5.0% | —— | —— | —— | $26.1M— | ||
| $26.13M+28.2% | $24.53M+34.4% | $24.33M+24.8% | $20.82M+3.5% | $20.38M+1.2% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $216.04M+35.0% | $215.51M+41.1% | $252.33M+87.1% | $153.31M+5.2% | $160.08M+9.0% | ||
| -$8.33M+18.8% | -$3.94M-118% | -$60.23M-247% | $12.14M-46.2% | -$10.26M-225% | ||
| -4%+2.8pp | -1.9%-14.2pp | -31.4%-54.6pp | 7.3%-6.1pp | -6.8%-4.7pp | ||
| $2.38M-46.2% | $2.02M-59.4% | $2.28M-44.4% | $4.53M+21.3% | $4.43M+30.3% | ||
| $21K+333% | —— | —— | —— | -$9K— | ||
| -$5.95M-2.0% | -$1.91M-107% | -$57.95M-229% | $16.67M-36.6% | -$5.83M-2,500% | ||
| -$3.66M-161% | —— | -$12.84M-299% | -$5.83M-191% | $6M+4,939% | ||
| -$2.29M+80.6% | -$4.11M-127% | -$45.12M-217% | $22.5M+13.0% | -$11.83M-9,638% | ||
| -1.1%+6.8pp | -1.9%-10.7pp | -23.5%-45.4pp | 13.6%+1.8pp | -7.9%-8.0pp | ||
| -$0.04+81.0% | -$0.07-126% | -$0.80-216% | $0.40+11.1% | -$0.21— | ||
| -$0.04+81.0% | -$0.07-125% | -$0.80-214% | $0.40+11.1% | -$0.21— | ||
| 57.6M+3.2% | 56.5M+0.9% | 56.6M+1.0% | 56.6M+1.6% | 55.9M+0.4% | ||
| 57.6M+3.2% | 56.5M+2.5% | 56.6M+2.5% | 56M+1.9% | 55.9M+1.9% | ||
| $8.48M+5.1% | —— | —— | —— | $8.07M— | ||
| $27.4M+5.0% | —— | —— | —— | $26.1M— | ||
| $8.48M+5.1% | —— | —— | —— | $8.07M— | ||
| $25.64M+29.6% | $24.53M+34.4% | $24.33M+24.8% | $20.82M+3.5% | $19.79M-1.7% | ||
| $2.39M-68.8% | $17.76M— | $0+100% | $0+100% | $7.66M+800% | ||
| $56.42M+21.3% | —— | —— | —— | $46.52M— | ||
| -$2.5M+78.8% | —— | —— | —— | -$11.8M— | ||
| -1%+4.0% | —— | —— | —— | -5%— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $21K+333% | —— | —— | —— | -$9K-500% | ||
| $5.92M+248% | $19M+26,493% | -$2.65M+59.1% | -$7.16M+11.7% | -$3.99M+27.2% | ||
| $0.62+160% | —— | —— | —— | -$1.03— | ||
| -$2.39M+68.8% | —— | —— | —— | -$7.66M— | ||
| $0-100% | —— | —— | —— | $25M— | ||
| $33.44M— | —— | —— | —— | —— | ||
| -$4.21M-314% | $1.97M— | $1.97M— | $1.97M— | $1.97M— | ||
| -$412K-250% | $271K-97.9% | $3.08M-84.3% | $12.42M-39.2% | $274K-18.5% | ||
| $49K-98.8% | -$491K-17.5% | -$21.53M-82.0% | -$6.49M+49.3% | $3.94M-60.7% | ||
| -$5.62M-258% | $16.42M+593% | $7.13M+201% | -$4.81M-201% | $3.56M-0.4% | ||
| $28.62M+1,904% | —— | —— | —— | $1.43M— | ||
| $105K+102% | $4.18M+231% | $12.94M+381% | -$4.89M+18.9% | -$4.73M-138% | ||
| $12.43M+269% | $6.91M-36.1% | $11.14M+536% | $2.5M— | -$7.37M-198% | ||
| $0— | —— | —— | —— | $0— | ||
| $1.5M-65.9% | —— | —— | —— | $4.4M— | ||
| $1.82M+232% | —— | —— | —— | $547K— | ||
| $192K-82.1% | —— | —— | —— | $1.07M— | ||
| $9.12M+143% | $8.53M+44.8% | $21.07M+585% | $935K-43.6% | -$21.4M-1,463% | ||
| -$19.22M-151% | —— | $48.71M+163% | —— | $37.32M+172% | ||
| $66.52M+117% | $19.86M-55.3% | —— | $58.54M+64.3% | $30.6M-20.3% | ||
| 9— | —— | —— | —— | —— | ||
| 1— | —— | —— | —— | —— | ||
| 1— | —— | —— | —— | —— | ||
| $2.26M+68.4% | —— | —— | —— | $1.34M-1.6% | ||
| -$211K-803% | —— | —— | —— | $30K— | ||
| -$211K-803% | —— | —— | —— | $30K— | ||
| -$284K+40.3% | —— | -$3.83M-127% | -$3.3M-14.6% | -$476K+72.3% | ||
| $2.38M-46.2% | $2.02M-59.4% | $2.28M-44.4% | $4.53M+21.3% | $4.43M+30.3% | ||
| $0-100% | $0— | $1.86M— | $2.3M— | $20.1M— | ||
| $0-100% | —— | —— | —— | $4.9M— | ||
| $4.56M+36.3% | $31K-96.9% | $811K+110% | $46K+4,500% | $3.34M+149% | ||
| $78.44M-33.8% | $90.2M-38.0% | $126.63M-43.7% | $140.56M+13.4% | $118.56M-38.8% | ||
| $0-100% | $427K+100% | $129K-35.5% | $455K+611% | $327K+31.9% | ||
| $13.67M+569% | $8.56M+24.4% | $23.74M+586% | $3.28M+97.5% | $2.04M-29.8% | ||
| $59.22M-62.1% | $39.32M-70.4% | $468.56M+216% | $110.4M+46.3% | $156.2M+9.8% | ||
| 50%— | —— | —— | —— | —— | ||
| $207.71M+38.6% | $211.57M+21.5% | $192.1M+9.3% | $165.45M-1.7% | $149.82M+4.3% | ||
| $8.48M+5.1% | $9.65M+26.5% | $7.83M+2.0% | $7.51M+14.6% | $8.07M+36.8% | ||
| 892.4K— | —— | —— | —— | —— | ||
| 19.5K— | —— | —— | —— | —— | ||
| $39.90— | —— | —— | —— | —— | ||
| $50.20— | —— | —— | —— | —— | ||
| $30.83— | —— | —— | —— | —— | ||
| 443.4K— | —— | —— | —— | —— | ||
| $9.12M+802% | —— | —— | —— | -$1.3M— | ||
| -$8.33M+18.8% | -$3.94M-118% | -$60.23M-247% | $12.14M-46.2% | -$10.26M-225% | ||
| $17.8M+75.8% | $21.08M-47.6% | -$35.43M-158% | $33.5M-22.6% | $10.13M-42.4% | ||
| $17.8M+75.8% | $21.08M-47.6% | -$35.43M-158% | $33.5M-22.6% | $10.13M-42.4% | ||
| 8.6%+1.8pp | 10%-13.1pp | -18.4%-53.1pp | 20.2%-5.5pp | 6.8%-5.5pp | ||
| -$8.33M+18.8% | -$3.94M-118% | -$60.23M-247% | $12.14M-46.2% | -$10.26M-225% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Supernus Pharmaceuticals's profit margins?
- Gross margin is 89.4% and operating margin is -7.8%, with a -3.7% net margin.
- Where does Supernus Pharmaceuticals's income statement data come from?
- Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.